Denise A. Yardley, MD

Articles

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

October 4th 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast Cancer

August 19th 2020

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Dr. Yardley on the FDA Approval of Talazoparib in Breast Cancer

October 16th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

Dr. Yardley Discusses Data With Talazoparib in Breast Cancer

August 27th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.

Dr. Yardley on the D-CARE Trial in Women With High-Risk Early Breast Cancer

July 31st 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the D-CARE trial in women with high-risk early breast cancer.

Dr. Yardley on the Role of Biosimilars in Breast Cancer

July 3rd 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the role of biosimilars in the treatment of patients with breast cancer.

Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

January 6th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

November 29th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Dr. Yardley Discusses CDK4/6 Inhibitors for Breast Cancer

October 30th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

October 26th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

September 15th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

August 3rd 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the unmet need for patients with HER2-positive breast cancer.

Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

June 20th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Dr. Denise Yardley on PI3K Inhibitors

January 29th 2015

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.

Dr. Yardley on Enzalutamide Plus Exemestane in HR-Positive Breast Cancer

May 31st 2014

Denise A. Yardley, MD, hematologist/oncologist, Sarah Cannon Research Institute discusses a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer when given enzalutamide plus exemestane.